Trevena to Release Fourth Quarter and Full Year 2020 Financial Results on March 9, 2021
05 mars 2021 07h00 HE
|
Trevena Inc.
-- Company to host conference call on March 9th, 2021, at 8:00 a.m. ET -- CHESTERBROOK, Pa., March 05, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused...
Trevena, Inc. to Participate in March Virtual Investor Conferences
01 mars 2021 07h00 HE
|
Trevena Inc.
CHESTERBROOK, Pa., March 01, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena, Inc. to Present at the 10th Annual SVB Leerink Global Healthcare Conference
22 févr. 2021 07h00 HE
|
Trevena Inc.
CHESTERBROOK, Pa., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central...
Trevena, Inc. Announces Publication Highlighting OLINVYK™ Respiratory Safety Data in High-Risk Patients in Pain & Therapy
28 janv. 2021 07h00 HE
|
Trevena Inc.
-- Low incidence of respiratory depression observed with OLINVYK (oliceridine) injection regardless of age or body mass index, in exploratory analysis -- CHESTERBROOK, Pa., Jan. 28, 2021 (GLOBE...
Trevena, Inc. to Participate in Two Upcoming Virtual Investor Conferences
07 janv. 2021 07h00 HE
|
Trevena Inc.
CHESTERBROOK, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena, Inc. Provides Update on Commercial Launch Activities for OLINVYK™ and Announces Anticipated Pipeline Catalysts
06 janv. 2021 07h00 HE
|
Trevena Inc.
-- Build-out of customer-facing team on track for this quarter OLINVYK comprehensive product dossier / health economic model now available to facilitate formulary reviews -- CHESTERBROOK, Pa.,...
Trevena, Inc. Announces Presentations Highlighting Novel S1P1 Receptor Modulator at the American College of Neuropsychopharmacology 59th Annual Meeting
10 déc. 2020 08h43 HE
|
Trevena Inc.
-- Presentations highlight efficacy of TRV045 in animal models of neuropathic pain and epilepsy TRV045 selectively targets the S1P1 receptor without associated lymphopenia IND filing on track for...
Trevena, Inc. Announces Publication Highlighting GI Tolerability Profile of OLINVYK™ (oliceridine) injection in Pain and Therapy
20 nov. 2020 07h00 HE
|
Trevena Inc.
-- OLINVYK significantly reduced risk of vomiting and rescue antiemetic use compared to IV morphine in a retrospective analysis -- CHESTERBROOK, Pa., Nov. 20, 2020 (GLOBE NEWSWIRE) --...
Trevena, Inc. to Participate in the Following November Virtual Investor Conferences
09 nov. 2020 07h00 HE
|
Trevena Inc.
-- Guggenheim Healthcare Talks - 2nd Annual Neuro/Immunology Day ConferenceNovember 16thStifel Virtual Healthcare ConferenceNovember 18th -- CHESTERBROOK, Pa., Nov. 09, 2020 (GLOBE NEWSWIRE) --...
Trevena, Inc. Announces DEA Scheduling of OLINVYK™ (oliceridine) injection
30 oct. 2020 07h44 HE
|
Trevena Inc.
-- OLINVYK commercial supply on track and available in November Company funded through Q4 2022, including OLINVYK commercialization -- Company to host conference call at 8:30 a.m. ET on Monday,...